These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28965748)

  • 1. The Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Adult Patients with Type 2 Diabetes: The Multicentre Randomized Controlled R
    Al Hamarneh YN; Hemmelgarn BR; Hassan I; Jones CA; Tsuyuki RT
    Can J Diabetes; 2017 Dec; 41(6):580-586. PubMed ID: 28965748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled R
    Al Hamarneh YN; Tsuyuki RT; Jones CA; Manns B; Tonelli M; Scott-Douglass N; Jindal K; Tink W; Hemmelgarn BR
    Am J Kidney Dis; 2018 Jan; 71(1):42-51. PubMed ID: 28912054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial.
    Tsuyuki RT; Al Hamarneh YN; Jones CA; Hemmelgarn BR
    J Am Coll Cardiol; 2016 Jun; 67(24):2846-54. PubMed ID: 27058907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a telephone-based intervention among patients with type-2 diabetes; a randomized controlled trial in pharmacy practice.
    Sarayani A; Mashayekhi M; Nosrati M; Jahangard-Rafsanjani Z; Javadi M; Saadat N; Najafi S; Gholami K
    Int J Clin Pharm; 2018 Apr; 40(2):345-353. PubMed ID: 29435911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Pharmacy-Based Interventions on the Control and Management of Diabetes in Adults: A Systematic Review and Meta-Analysis.
    Yaghoubi M; Mansell K; Vatanparastc H; Steeves M; Zeng W; Farag M
    Can J Diabetes; 2017 Dec; 41(6):628-641. PubMed ID: 29224636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community Pharmacists Assisting in Total Cardiovascular Health (CPATCH): A Cluster-Randomized, Controlled Trial Testing a Focused Adherence Strategy Involving Community Pharmacies.
    Blackburn DF; Evans CD; Eurich DT; Mansell KD; Jorgenson DJ; Taylor JG; Semchuk WM; Shevchuk YM; Remillard AJ; Tran DA; Champagne AP
    Pharmacotherapy; 2016 Oct; 36(10):1055-1064. PubMed ID: 27581815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist-Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (R
    Tam-Tham H; Clement F; Hemmelgarn BR; Manns BJ; Klarenbach SW; Tonelli M; Tsuyuki RT; Al Hamarneh YN; Penko J; Weaver CGW; Au F; Weaver RG; Jones CA; McBrien KA
    Value Health; 2019 Oct; 22(10):1128-1136. PubMed ID: 31563255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
    Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
    Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN).
    McLean DL; McAlister FA; Johnson JA; King KM; Makowsky MJ; Jones CA; Tsuyuki RT;
    Arch Intern Med; 2008 Nov; 168(21):2355-61. PubMed ID: 19029501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R
    Al Hamarneh YN; Marra C; Gniadecki R; Keeling S; Morgan A; Tsuyuki R
    BMJ Open; 2021 Mar; 11(3):e043612. PubMed ID: 33762234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cluster-Randomized Trial to Evaluate a Centralized Clinical Pharmacy Service in Private Family Medicine Offices.
    Carter BL; Levy B; Gryzlak B; Xu Y; Chrischilles E; Dawson J; Vander Weg M; Christensen A; James P; Polgreen L
    Circ Cardiovasc Qual Outcomes; 2018 Jun; 11(6):e004188. PubMed ID: 29884657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes and cardiovascular disease interventions by community pharmacists: a systematic review.
    Evans CD; Watson E; Eurich DT; Taylor JG; Yakiwchuk EM; Shevchuk YM; Remillard A; Blackburn D
    Ann Pharmacother; 2011 May; 45(5):615-28. PubMed ID: 21558487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial.
    Simpson SH; Lier DA; Majumdar SR; Tsuyuki RT; Lewanczuk RZ; Spooner R; Johnson JA
    Diabet Med; 2015 Jul; 32(7):899-906. PubMed ID: 25594919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus).
    Yamada C; Johnson JA; Robertson P; Pearson G; Tsuyuki RT
    Pharmacotherapy; 2005 Jan; 25(1):110-5. PubMed ID: 15767226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes.
    Chan CW; Siu SC; Wong CK; Lee VW
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):57-64. PubMed ID: 21335480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Dader Method for pharmaceutical care on control of blood pressure and total cholesterol in outpatients with cardiovascular disease or cardiovascular risk: EMDADER-CV randomized controlled trial.
    Amariles P; Sabater-Hernández D; García-Jiménez E; Rodríguez-Chamorro MÁ; Prats-Más R; Marín-Magán F; Galán-Ceballos JA; Jiménez-Martín J; Faus MJ
    J Manag Care Pharm; 2012 May; 18(4):311-23. PubMed ID: 22548691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk.
    Tsuyuki RT; Johnson JA; Teo KK; Ackman ML; Biggs RS; Cave A; Chang WC; Dzavik V; Farris KB; Galvin D; Semchuk W; Simpson SH; Taylor JG
    Ann Pharmacother; 1999 Sep; 33(9):910-9. PubMed ID: 10492489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacist-to-prescriber intervention to close therapeutic gaps for statin use in patients with diabetes: A randomized controlled trial.
    Renner HM; Hollar A; Stolpe SF; Marciniak MW
    J Am Pharm Assoc (2003); 2017; 57(3S):S236-S242.e1. PubMed ID: 28506378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding pharmacists to primary care teams increases guideline-concordant antiplatelet use in patients with type 2 diabetes: results from a randomized trial.
    Gilani F; Majumdar SR; Johnson JA; Tsuyuki RT; Lewanczuk RZ; Spooner R; Simpson SH
    Ann Pharmacother; 2013 Jan; 47(1):43-8. PubMed ID: 23324512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes.
    Cohen LB; Taveira TH; Khatana SA; Dooley AG; Pirraglia PA; Wu WC
    Diabetes Educ; 2011; 37(6):801-12. PubMed ID: 22021025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.